CRISPR Therapeutics Reports Q3 2025 Revenue Increase to $889,602 Amid Rising Net Loss

CRISPR Therapeutics AG reported its financial results for the third quarter and the first nine months of 2025, revealing a total revenue of $889,602 for the quarter, a significant increase from $2,646 in the same period last year. For the nine months ending September 30, 2025, total revenue reached $2,646, compared to $1,623 in the prior year. The company did not generate any collaboration revenue during these periods, with grant revenue being the sole contributor to the reported figures. The net loss for the third quarter was $106.4 million, compared to a loss of $85.9 million in the same quarter of 2024. For the nine-month period, the net loss was $451.0 million, up from $328.9 million in the previous year.

Operating expenses for the third quarter totaled $132.9 million, an increase from $110.7 million in the same quarter of 2024. This rise was primarily driven by a substantial increase in collaboration expenses, which surged to $57.1 million from $11.2 million year-over-year, reflecting higher operational costs associated with the CASGEVY program. Research and development expenses decreased to $58.9 million from $82.2 million, attributed to reduced external research costs and a decrease in employee-related expenses due to a lower headcount. General and administrative expenses also saw a slight decline, totaling $16.9 million compared to $17.4 million in the prior year.

In terms of strategic developments, CRISPR Therapeutics entered into a collaboration agreement with Sirius Therapeutics in May 2025, which included an upfront cash payment of $25 million and the issuance of common shares valued at approximately $70 million. This partnership aims to develop therapies utilizing Sirius' siRNA technology. The company also reported a significant acquisition of in-process research and development expenses amounting to $96.3 million related to this agreement, marking a notable investment in its research capabilities.

As of September 30, 2025, CRISPR Therapeutics held $1.9 billion in total assets, with cash and cash equivalents amounting to $286.5 million, a slight decrease from $298.3 million at the end of 2024. The company’s total liabilities increased to $329.3 million from $310.0 million, primarily due to higher accrued expenses. The total shareholders' equity stood at $1.9 billion, down from $1.9 billion at the end of the previous fiscal year, reflecting the ongoing net losses.

Looking ahead, CRISPR Therapeutics anticipates that its existing cash, cash equivalents, and marketable securities will support its operations for at least the next 24 months. The company plans to continue its focus on research and development, particularly in advancing its gene-editing technologies and therapies. However, it acknowledges the need for additional capital to fund its long-term clinical development and commercialization efforts, which may involve raising funds through equity or debt financing, as well as collaboration agreements.